Skip to main content
SpringerLink
Log in

B-Cell Prolymphocytic Leukemia (B-PLL) and T-Cell Prolymphocytic Leukemia (T-PLL)

  • Chapter
  • First Online:
Rare Lymphomas

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1178 Accesses

Abstract

Both prolymphocytic leukemia of T-cell (T-PLL) and B-cell (B-PLL) phenotype are rare and aggressive malignancies characterized by marked lymphocytosis and splenomegaly. Given the poor response to conventional therapy including alkylating agents or purine analogues, overall survival in most cases is less than 12 months. Monoclonal antibodies, e.g., rituximab in B-PLL and alemtuzumab in B-PLL and T-PLL, demonstrated encouraging activity in terms of response. However, long-term survival is rare, and allogeneic transplant might be considered as an option in selected patients.

Pathology: German Ott, Eric D. Hsi

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96(3):617–619

    Article  CAS  PubMed  Google Scholar 

  • Campo E et al (2008) B-cell prolymphocytic leukaemia. In: Swerdlow SH et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon

    Google Scholar 

  • Castagna L, Sarina B, Todisco E, Mazza R, Santoro A (2005) Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant 35(12):1225. doi:1704991 [pii];10.1038/sj.bmt.1704991 [doi]

    Article  CAS  PubMed  Google Scholar 

  • Catovsky D (1982) Prolymphocytic leukaemia. Nouv Rev Fr Hematol 24(6):343–347

    CAS  PubMed  Google Scholar 

  • Chaar BT, Petruska PJ (2007) Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol 82(5):417. doi:10.1002/ajh.20843

    Article  PubMed  Google Scholar 

  • Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L (2011) Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 87(5):426–433. doi:10.1111/j.1600-0609.2011.01680.x

    Article  CAS  PubMed  Google Scholar 

  • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6):631–636. doi:10.1200/jco.2011.37.4223

    Article  CAS  PubMed  Google Scholar 

  • Collins RH, Pineiro LA, Agura ED, Fay JW (1998) Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 21(6):627–628

    Article  CAS  PubMed  Google Scholar 

  • Curtin NJ, Schwarer AP (2005) Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol 27(3):206–208

    Article  CAS  PubMed  Google Scholar 

  • Davi F, Maloum K, Michel A, Pritsch O, Magnac C, Macintyre E, Salomon-Nguyen F, Binet JL, Dighiero G, Merle-Beral H (1996) High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 88(10):3953–3961

    CAS  PubMed  Google Scholar 

  • de Lavallade H, Faucher C, Furst S, El Cheikh J, Vey N, Coso D, Bouabdallah R, Stoppa AM, Gastaut JA, Blaise D, Mohty M (2006) Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission. Bone Marrow Transplant 37(7):709–710

    Article  PubMed  Google Scholar 

  • Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120(3):538–551. doi:blood-2012-01-380139 [pii];10.1182/blood-2012-01-380139 [doi]

    Article  CAS  PubMed  Google Scholar 

  • Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98(6):1721–1726

    Article  CAS  PubMed  Google Scholar 

  • Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D (2011) Alemtuzumab therapy in T-cell prolymphocytic leukaemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118(22):5799–5802

    Article  CAS  PubMed  Google Scholar 

  • Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D (2006) IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 20(7):1231–1237. doi:10.1038/sj.leu.2404238 [pii];

    Google Scholar 

  • Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. The New England journal of medicine 366(21):2038–2040.

    Google Scholar 

  • Dunphy CH, Perkins SL (2001) Mantle cell leukemia, prolymphocytoid type: a rarely described form. Leuk Lymphoma 41(5–6):683–687

    Article  CAS  PubMed  Google Scholar 

  • Dyer MJ, Hale G, Hayhoe FG, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73(6):1431–1439

    CAS  PubMed  Google Scholar 

  • Galton DA, Goldman JM, Wiltshaw E, Catovsky D, Henry K, Goldenberg GJ (1974) Prolymphocytic leukaemia. Br J Haematol 27(1):7–23

    Article  CAS  PubMed  Google Scholar 

  • Garand R, Goasguen J, Brizard A, Buisine J, Charpentier A, Claisse JF, Duchayne E, Lagrange M, Segonds C, Troussard X, Flandrin G (1998) Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d’Hematologie Cellulaire. Br J Haematol 103(2):488–494

    Article  CAS  PubMed  Google Scholar 

  • Garderet L, Bittencourt H, Kaliski A, Daniel M, Ribaud P, Socie G, Gluckman E (2001) Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol 66(2):137–139

    Article  CAS  PubMed  Google Scholar 

  • Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22(2):185–191

    Article  CAS  PubMed  Google Scholar 

  • Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 23(5):1098–1104

    Article  CAS  PubMed  Google Scholar 

  • Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P (2004) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104(4):948–955

    Article  CAS  PubMed  Google Scholar 

  • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174. doi:S0140-6736(10)61381-5 [pii];10.1016/S0140-6736(10)61381-5 [doi]

    Article  CAS  PubMed  Google Scholar 

  • Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale G, Waldmann H, Heimpel H (1986) Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 64(3):479–486

    Article  CAS  PubMed  Google Scholar 

  • Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F, Vandeputte H, Albert A, Maynadie M, Troussard X, Simon GH, Lespinasse J, Portefaix G, Merle-Beral H (2001) A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 42(5):981–987

    Article  CAS  PubMed  Google Scholar 

  • Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D (2004) A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 104(2):328–335

    Article  CAS  PubMed  Google Scholar 

  • Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D (2008) High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 111(1):328–337

    Article  CAS  PubMed  Google Scholar 

  • Herold M, Spohn C, Schlag R et al (2003) Fludarabine/cyclophosphamide chemotherapy for B – prolymphocytic leukaemia. Blood 102(abstract):2499

    Google Scholar 

  • Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Dohner H, Kandler G, Eichhorst B, Hallek M, Herling M (2013) Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. doi:10.1002/cncr.27972

    PubMed  Google Scholar 

  • Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M (2010) Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biology of Blood and Marrow Transplant 16(4):543–547

    Article  Google Scholar 

  • Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20(1):205–213

    Article  CAS  PubMed  Google Scholar 

  • Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE (2010) Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 149(6):907–910

    Article  PubMed  Google Scholar 

  • Kruspe RC, Ashraf KK, Foran JM, Salzman DE, Reddy VV, Vaughan WP (2007) Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation. Clin Adv Hematol Oncol 5(11):882–884

    PubMed  Google Scholar 

  • Lampert I, Catovsky D, Marsh GW, Child JA, Galton DA (1980) The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia. Histopathology 4(1):3–19

    Article  CAS  PubMed  Google Scholar 

  • Langabeer SE, Quinn F, O’Brien D, McElligott AM, Kelly J, Browne PV, Vandenberghe E (2012) Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res 36(4):483–484. doi:0145-2126(11)00606-0 [pii];10.1016/j.leukres.2011.12.015 [doi]

    Article  CAS  PubMed  Google Scholar 

  • Lennert KFA (1992) Histopathology of non-Hodgkin’s lymphomas, 2nd edn. Springer, New York

    Book  Google Scholar 

  • Lens D, Matutes E, Catovsky D, Coignet LJ (2000) Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 14(3):427–430

    Article  CAS  PubMed  Google Scholar 

  • Matutes E (1998) T-cell prolymphocytic leukemia. Cancer Control 5(1):19–24

    PubMed  Google Scholar 

  • Matutes E (2012) Novel and emerging drugs for rarer chronic lymphoid leukaemias. Curr Cancer Drug Targets 12(5):484–504. doi:CCDT-EPUB-20120403-004 [pii]

    Article  CAS  PubMed  Google Scholar 

  • Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, Sempere A, Catovsky D (1991) Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78(12):3269–3274

    CAS  PubMed  Google Scholar 

  • Matutes E, Wotherspoon A, Catovsky D (2003) The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 16(1):41–56

    Article  CAS  PubMed  Google Scholar 

  • Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D (1994) The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12(12):2588–2593

    CAS  PubMed  Google Scholar 

  • Mourad YA, Taher A, Chehal A, Shamseddine A (2004) Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 83(5):319–321. doi:10.1007/s00277-003-0805-z

    Article  PubMed  Google Scholar 

  • Murase K, Matsunaga T, Sato T, Kuribayashi K, Kogawa K, Kawano Y, Okamoto T, Takayama T, Watanabe H, Niitsu Y, Hirayama Y (2003) Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement. Int J Clin Oncol 8(6):391–394

    Article  PubMed  Google Scholar 

  • Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, Hofmann WK, Ogawa S, Koeffler HP (2009) Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica 94(4):518–527

    Article  CAS  PubMed  Google Scholar 

  • O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 29(9):1182–1189. doi:JCO.2010.29.9024 [pii];10.1200/JCO.2010.29.9024 [doi]

    Article  PubMed  Google Scholar 

  • Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T (2005) Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia. Rinsho Ketsueki 46(7):527–531

    PubMed  Google Scholar 

  • Osuji N, Matutes E, Catovsky D, Lampert I, Wotherspoon A (2005) Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review. Am J Surg Pathol 29(7):935–941

    Article  PubMed  Google Scholar 

  • Ozpuyan F, Meyer P, Ni H, Al Masri H, Alkan S (2007) Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL). Leuk Lymphoma 48(11):2247–2250

    Article  CAS  PubMed  Google Scholar 

  • Pamuk GE, Puyan FO, Unlu E, Ozturk E, Demir M (2009) The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication. Leuk Res 33(6):864–867. doi:S0145-2126(08)00393-7 [pii];10.1016/j.leukres.2008.09.013 [doi]

    Article  PubMed  Google Scholar 

  • Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15(7):2667–2672

    CAS  PubMed  Google Scholar 

  • Pekarsky Y, Hallas C, Isobe M, Russo G, Croce CM (1999) Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. Proc Natl Acad Sci USA 96(6):2949–2951

    Article  CAS  PubMed  Google Scholar 

  • Put N, Van RK, Konings P, Meeus P, Brusselmans C, Rack K, Gervais C, Nguyen-Khac F, Chapiro E, Radford-Weiss I, Struski S, Dastugue N, Gachard N, Lefebvre C, Barin C, Eclache V, Fert-Ferrer S, Laibe S, Mozziconacci MJ, Quilichini B, Poirel HA, Wlodarska I, Hagemeijer A, Moreau Y, Vandenberghe P, Michaux L (2012) Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Ann Hematol 91(6):863–873. doi:10.1007/s00277-011-1393-y

    Article  CAS  PubMed  Google Scholar 

  • Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H (2009) Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425–5430

    Article  CAS  PubMed  Google Scholar 

  • Rondelli D, Lauria F, Zinzani PL, Raspadori D, Ventura MA, Galieni P, Birtolo S, Forconi F, Algeri R, Tura S (1997) 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 58(1):46–50

    Article  CAS  PubMed  Google Scholar 

  • Rowan W, Tite J, Topley P, Brett SJ (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95(3):427–436

    Article  CAS  PubMed  Google Scholar 

  • Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E, Catovsky D (2004) B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 125(3):330–336

    Article  PubMed  Google Scholar 

  • Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L (1997) Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 15(1):37–43

    CAS  PubMed  Google Scholar 

  • Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A (1999) B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33(1–2):169–179. doi:10.3109/10428199909093739

    CAS  PubMed  Google Scholar 

  • Shvidel L, Shtalrid M, Klepfish A, Haran M, Berrebi A (2000) Successful autologous stem cell transplantation in aggressive prolymphocytic leukemia. Am J Hematol 63(4):230–231. doi:10.1002/(SICI)1096-8652(200004)63:4%3C230::AID-AJH12%3E3.0.CO;2-5 [pii]

    Google Scholar 

  • Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy–-CHOP. Br J Haematol 42(3):488–490

    Article  CAS  PubMed  Google Scholar 

  • Singleton TP, Anderson MM, Ross CW, Schnitzer B (1999) Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol 111(4):495–500

    CAS  PubMed  Google Scholar 

  • Soma L, Cornfield DB, Prager D, Nowell P, Bagg A (2002) Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol 71(3):224–226

    Article  PubMed  Google Scholar 

  • Stern MH, Soulier J, Rosenzwajg M, Nakahara K, Canki-Klain N, Aurias A, Sigaux F, Kirsch IR (1993) MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 8(9):2475–2483

    CAS  PubMed  Google Scholar 

  • Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A, James MR, Lichter P, Dohner H (1997) Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3(10):1155–1159

    Article  CAS  PubMed  Google Scholar 

  • Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, Busch R, Hensel M, Duhrsen U, Finke J, Dreger P, Jager U, Lengfelder E, Hohloch K, Soling U, Schlag R, Kneba M, Hallek M, Dohner H (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27(24):3994–4001

    Article  CAS  PubMed  Google Scholar 

  • Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

    Google Scholar 

  • Tanimoto TE, Hirano A, Nagafuji K, Yamasaki S, Hashiguchi M, Okamura T, Kamezaki K, Takase K, Numata A, Miyamoto T, Fukuda T, Harada M (2005) Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia. Leukemia 19(4):679–681

    CAS  PubMed  Google Scholar 

  • Vartholomatos G, Tsiara S, Christou L, Panteli A, Kaiafas P, Bourantas KL (1999) Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 102(2):94–98. doi:40977 [pii]

    Article  CAS  PubMed  Google Scholar 

  • Viswanatha DS et al (2012) Mature B cell neoplasms: chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, and lymphoplasmocytic leukemia. In: Jaffe ES et al (eds) Hematopathology. Elsevier, Philadelphia

    Google Scholar 

  • Weide R, Pandorf A, Heymanns J, Koppler H (2004) Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45(12):2445–2449. doi:TGAY99TY8R1N4B44 [pii];10.1080/10428190400004521 [doi]

    Article  CAS  PubMed  Google Scholar 

  • Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578–4587

    Article  CAS  PubMed  Google Scholar 

  • Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P (2012) Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia 26(5):972–976

    Article  CAS  PubMed  Google Scholar 

  • Wong KF, So CC, Chan JK (2002) Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol 117(2):246–251

    Article  PubMed  Google Scholar 

  • Yong HX, Linn YC, Ong KH, Tan D (2012) Chemoimmunotherapy with bendamustine hydrochloride and alemtuzumab demonstrates synergism in T-prolymphocytic leukemia. Leuk Res 36(8):e163–e165

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany

    German Ott MD

  2. Department of Clinical Pathology, Cleveland Clinic, L11, 9500 Euclid Ave, Cleveland, OH, 44195, USA

    Eric D. Hsi MD

  3. Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett St, Melbourne, VIC, 8006, Australia

    John F. Seymour

  4. 3rd Department of Internal Medicine with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Salzburger Landeskliniken, Paracelsus Medical University, Salzburg, Austria

    Georg Hopfinger

Authors
  1. German Ott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric D. Hsi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John F. Seymour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georg Hopfinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to German Ott MD .

Editor information

Editors and Affiliations

  1. Medizinischen Klinik und Poliklinik III, Universität München Klinikum Großhadern, München, Germany

    Martin Dreyling

  2. Division of Hematology/Oncology and Cancer Center, University of Virginia Health System, Charlottesville, Virginia, USA

    Michael E. Williams

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ott, G., Hsi, E.D., Seymour, J.F., Hopfinger, G. (2014). B-Cell Prolymphocytic Leukemia (B-PLL) and T-Cell Prolymphocytic Leukemia (T-PLL). In: Dreyling, M., Williams, M. (eds) Rare Lymphomas. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-39590-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-39590-1_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-39589-5

  • Online ISBN: 978-3-642-39590-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation